Regavirumab
Monoclonal antibody
NY (what is this?) (verify) Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.[1]
References
- ^ Arizono H, Sugano T, Kaida S, Shibusawa K, Karasawa Y, Esumi Y, et al. (July 1994). "Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys". Arzneimittel-Forschung. 44 (7): 909–13. PMID 7945531.
- v
- t
- e
Monoclonal antibodies for infectious disease and toxins
Human |
|
---|
Human |
|
---|---|
Chimeric | |
Humanized |
Human | |
---|---|
Mouse | |
Chimeric | |
Humanized |
Human | |
---|---|
Chimeric | |
Humanized |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e